title: Cost-Utility Analysis of Simeprevir With Peginterferon + Ribavirin (SMV/PR) in the Management of Genotype 1 (G1) and 4 (G4) Hepatitis C Virus (HCV) Infection; from the Perspective of the Uk National Health Service (NHS).
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: K Y
authors.initials: KY
authors.lastname: Westerhout
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Treur
authors.affiliation: Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Mehnert
authors.affiliation: Janssen-Cilag Ltd, Buckinghamshire, UK.
authors.forename: K
authors.initials: K
authors.lastname: Pascoe
authors.affiliation: Janssen-Cilag Ltd, Buckinghamshire, UK.
authors.forename: I
authors.initials: I
authors.lastname: Ladha
authors.affiliation: JB Medical Ltd, Sudbury, UK.
authors.forename: J
authors.initials: J
authors.lastname: Belsey